healthcaretrends

The growth of a interventional oncology market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research.

Market Growth Analysis:
The global Interventional Oncology Market is projected to reach $2.9 billion in coming years.

To Gain Crucial Insights Into the Market | Download PDF Brochure Now:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164

Ablation Devices Segment Growing at a Highest Rate:

The interventional oncology industry is segmented into ablation devices, embolization devices, and support devices. The embolization devices segment accounted for the largest share of the interventional oncology market in 2018. The large share of this segment can be attributed to the rising prevalence of cancer, product enhancements, and the increasing adoption of Yttrium-90 radioembolic agents in emerging countries.

Transcatheter Arterial Chemoembolization (TACE) and Selective Internal Radiation Therapy (SIRT):

the global interventional oncology industry is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. In 2018, the TARE/SIRT procedures segment accounted for the largest market share majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents (which are used in these procedures).

The Liver Cancer Segment Accounted For The Largest Share Of The Interventional Oncology Market:

The interventional oncology market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other cancers (includes pediatric cancer, prostate cancer, and breast cancer). The liver cancer segment accounted for the largest share of the interventional oncology market in 2018. The large share of this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities for developing advanced liver cancer therapies using interventional oncology.

Geographical Growth Analysis:

The Asia Pacific regional market is expected to grow at the highest CAGR during the forecast period. Emerging economies in the region such as India, China, and South Korea, along with developed markets such as Japan and Australia, are offering high-growth opportunities for market players in the field of interventional oncology. This can be attributed to factors such as the increasing adoption of interventional oncology procedures, growing incidence of cancer, and the growing geriatric population.

Get Expert Analysis and Insights of Global Market | Download Sample Report:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=203687164

Key Market Players:

The major players operating in the interventional oncology market include BTG plc (UK), Medtronic (Ireland), Boston Scientific (US), Terumo (Japan), Merit Medical (US), Sirtex (China), AngioDynamics (US), Ethicon (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves Medical (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), and Trisalus Lifesciences (US), among others.